| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $8.9M | -25.1% |
| SG&A Expense | $11.5M | +32.2% |
| Net Income | -$16.3M | +4.3% |
| EPS (Basic) | -$1.08 | -1100.0% |
| EPS (Diluted) | -$1.47 | -1370.0% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $12.7M | -62.7% |
| Current Assets | $13.3M | -62.6% |
| Total Assets | $13.6M | -65.0% |
| Current Liabilities | $1.2M | -76.7% |
| Total Liabilities | $1.8M | -84.4% |
| Stockholders' Equity | $11.8M | -56.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$21.1M | -50.0% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $0 | +100.0% |
| Financing Cash Flow | -$111K | -100.4% |
| Free Cash Flow | -$21.1M | -48.9% |